🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden flag Sweden · Delayed Price · Currency is SEK
3.680
-0.120 (-3.16%)
Nov 20, 2026, 5:29 PM CET
← View all transcripts

BioStock Life Science Summit 2026

Nov 4, 2026

Summary

The discovery-only model combines fragment-based design, structural biology and an in-house DMTA engine to build a broad, partner-ready oncology portfolio. Lilly TuneLab adds AI-based ADME prediction; the five disclosed programs are ready for partnering.

Johan Emilsson
CEO, Sprint Bioscience

I will introduce you to Sprint Bioscience, how we operate, what we do, and how we actually are being able to monetize on the science that we create in our labs. In short, for those of you that have not been introduced to Sprint before, we are a company that primarily focus on oncology drug discovery. We are a little bit different in the sense that we are only focusing in the very first part of drug development, the drug discovery part, and we do not touch the regulatory part of drug development. In a sense, we are purely an asset creation company and focusing on building a broad portfolio of a number of different programs that we find partnerships for. We do this by utilizing a process called fragment-based drug design, and I will come back a little bit more in detail on how we actually do it.

We do have multiple projects in early stage. We have been around for a while. We were founded in 2009. We went public in 2014. We have a background where we came from not an academic track, but rather from a number of persons from the industry come together, seeing the opportunities being created with the fragment-based drug design and how that could revolutionize the way you work with small molecules. We are based in Stockholm, and we are today a bit north of 30 employees. How it is done. What we do, we are looking for primarily intracellular proteins that one way or another is regulating the disease, and primarily then in oncology. We are looking to find this protein. Normally, as you can see here, is that you have the protein, but it also has, of course, a biological function.

You can see the red here in the dark red one in the middle protein rendering, you have kind of how it works normally. It sounds easy, but we then develop an inhibitor to stop that. This is a very design-driven approach. When we do our inhibitors and how we do it, is we do not guess. This is a very structured approach on how to do it. It would also be wrong for me being in Lund and not mentioning one of our critical equipments located, I believe, in that direction, which is MAX IV. We are actually one of the biggest industry users of MAX IV. We, together with AstraZeneca and SARomics Biostructures, are the ones that are utilizing the BioMAX beam the most.

What we actually do is that when we have isolated the protein that we want to work with, we can utilize this beam to get a 3D picture of exactly how this protein looks. We can also, when we are starting to do our molecules, actually also see exactly how the molecules is sitting inside of the protein. To be able to do this in an efficient way, we have over the years built capabilities to have a very efficient machinery to optimize these small molecules to be very potent and selective inhibitors. We live and breathe our DMTA cycle. It is the design, make, test, analyze cycle. That is how we built an integrated discovery engine internally, where we have the capabilities in our own labs to be able to build these molecules.

So that means that when we have isolated protein, we have got the 3D picture and understanding how it looks, we have an understanding of our first prototypes on how the molecule looks and how it sits into the protein, our computational and medicinal chemistry team work together to do the design and compute how, to the best of our understanding and the knowledge we have at that point of time, what would be the optimal molecule.

Then we have our own labs to make the medicinal chemistry and do the molecules, and then we have all of the internal capabilities to test how it works, our own cell biology labs. Then that analyze feed goes back into the design phase, and this then becomes an iterative step and optimizes the way we are then going forward and creating the most optimal molecule. So that is essentially how we do it.

But also, our business model is slightly different compared to other companies. As I said, we are a discovery-only company. That also means that we have the opportunity to, with fairly limited resources, run a fairly broad portfolio of different programs, which means that by focusing on licensing early to pharmaceutical companies, we make several small bets. But what we have also proven through history, we can also get significant revenues from. So we are focusing on the early stage, but also then retaining the opportunities to get the money coming later on, so getting milestones and royalties in the end during the development progress as it then progress with the companies we work with. So how do we monetize it? We have over the years done six deals with different pharmaceutical companies.

Primarily, we have done the kind of the classic license agreement where companies have come to us and then licensed our know-how and our IP. We have done that with companies such as Day One Biopharmaceuticals, a couple of deals with smaller companies such as Petra Pharma and Deciphera, but also historically also a collaboration we had with Bayer back in the days. But I would say that the biggest deal we did was actually just before the holidays when we sold our TREX1 program to Gilead. Gilead acquired our TREX1 program in November last year, where we got a $40 million upfront and a total deal value of that program of $400 million. And that essentially was an acquisition where they acquired one of our programs.

We have historically also worked in one of the agreements we had when we were collaborating with Day One Biopharmaceuticals was that we had also had a research component to it where we continued to work on the program and develop that, which also meant we got research revenues from that. The benefit of having a broad portfolio is that we can also be a little bit agnostic in the way we transact. That means that we are having discussions with companies that are looking for other ways to interact with us and work with us. One of those is a company creation track where every program we have in our portfolio is essentially an excellent starting point for a new biotech. And it is an opportunity for us to have discussions with other parties that are looking into our portfolio and looking at, "Well, this program would be perfect.

We will put our own management team to it, and we will fund that. That is one way of doing it. Another opportunity is for companies. We have had a number of interactions over the years that kind of looked into the machinery we have built, where we are also now opening it up for having discussion about the development and option agreement, where they come with the target, one target or more targets that we can collaborate around. If we are successful and we generate good IP on that, they have then the option to either license or acquire it. In the age of AI, it would be strange not to mention the collaboration we started during the summer. During the summer, we went into a collaboration with Lilly and their Lilly TuneLab platform.

That is an opportunity for us because we have, from the very beginning, we have been very data-driven in the approach how we build our small molecules. So we have a data set up and a special competence called computational chemistry that works in making sure that we can do very specific and very potent molecules. However, where we do lack some capabilities is in the later stage, and that is where we teamed up with Lilly, where they came to us and asked, "We see you do great things. You have a lot of data and a lot of experience.

Do you want to collaborate on the later part in your stage of kind of developing these molecules, which is the ADME part, and like what happens when your molecules enters into the body?" So we are now teaming up with Lilly and starting to implement their TuneLab setup, which is essentially an AI platform to be able to then predict from the molecules we are making which one will have the best ADME properties and will work the best when they actually enter the body. So quickly on the portfolio, we have five publicly disclosed compounds or programs in our portfolio. It is our VRK1 and DCPS programs. It is within synthetic lethality in the space of oncology. We have VPS34, which is in autophagy.

Then we have two programs that is in the interface between oncology and I&I, so immunology and inflammation, which is our STK25 inhibitor and our NNMT inhibitor. All of these have reached a maturity stage where we find them ready to be partnered and are actively looking to do so. To that, we have also an additional pipeline with undisclosed programs because we are continuously testing new theories and prototyping inside of our labs. So we have proven that we can repeatedly monetize our programs. We have a diverse portfolio strategy. It is very time and cost efficient. In the age of AI, we also have an AI-enabled development capability with very structured and good data. I am happy to take any question, ending with a picture from one of our chemistry labs. Thank you very much.

Moderator

Thank you, Johan. Do we have any questions from the room? We do. Perfect. I was going to say, you owe me a question, so that's good.

Speaker 3

Do you see yourself as a-

Moderator

Just take the microphone. Yes.

Speaker 3

Do you see yourself as a super modern discovery company?

Johan Emilsson
CEO, Sprint Bioscience

As a super modern

Speaker 3

Super modern.

Johan Emilsson
CEO, Sprint Bioscience

Yeah, I mean, I would say we're a super modern discovery company or something that has matured in keeping up with the ages and continuously looking at how we can do things quicker, better, efficiently, but retaining good quality.

Speaker 3

At what stage do you like to approach a company, for example?

Johan Emilsson
CEO, Sprint Bioscience

We are approaching companies very, very early, and it's important for us because it's an ongoing. You get a lot of good feedback during the interactions you have. We're extremely active from a business development perspective. As mentioned, we've been around for 17 years, so we kind of retain a very good brand. We have a good brand equity out with the industry, which also means we have a lot of good feedback sessions on that perspective. We interact from early prototyping, all the way to where we're at now with some of the programs we have in the portfolio. Some have been transacted really early and some later.

Speaker 3

The proteins you work with, is that mainly the crystal structure or is it other parts?

Johan Emilsson
CEO, Sprint Bioscience

For us, it's very important that we can get the crystal structures to be able to work with machinery and work with MAX IV. Yes.

Speaker 3

That's perfect. Thanks.

Moderator

Got another gentleman over here.

Speaker 4

Thanks. Very interesting approach. I was wondering about your approach to select targets. You mentioned you were a very data-driven company.

Johan Emilsson
CEO, Sprint Bioscience

Absolutely.

Speaker 4

What's your approach to selecting targets?

Johan Emilsson
CEO, Sprint Bioscience

The different kind of targets come from different areas, right? We've been very focusing on the kind of immuno-oncology track and where we can modulate the immune system utilizing small molecules. Having said that, we are constantly looking at what's happening in the landscape. It's a lot of interaction. Out of the 30+ employees I have, we have 84% PhDs, so I have a lot of ideas internally as well. So, it's a mix, but a very collaborative approach to it.

Speaker 4

What I meant to ask was the data-driven approach you mentioned.

Johan Emilsson
CEO, Sprint Bioscience

Yeah

Speaker 4

It is related to compounds and fragments. With respect to targets, is there any collecting real-world data or the data from public resources?

Johan Emilsson
CEO, Sprint Bioscience

Yeah. We have internal bioinformatics capabilities as well, which means that we were constantly looking at that. Yeah. It is truly a very data-driven approach to both the development but also identification of new targets.

Moderator

As a final question then, tying into the deal panel that we heard earlier, they talked about these kind of partner discussions taking years and years, and obviously you do deals. How long do they take for you?

Johan Emilsson
CEO, Sprint Bioscience

I think I can reflect back on the answers during the panel. It is very hard to say when it is only a discussion and when it is actually starting to be discussion about deal terms. Those are two different things. There are companies we have been having discussions with for over 15 years and have not made a deal with, and there are some companies we had discussions for a shorter time and made deals with. It is very transaction to transaction.

Moderator

It varies.

Johan Emilsson
CEO, Sprint Bioscience

Yeah.

Moderator

Thank you so much, Johan.

Johan Emilsson
CEO, Sprint Bioscience

Thank you.